Biotech Values

[DewDiligence]

TTPH +22% AH on buyout chatter:

http://www.bloomberg.com/news/2014-11-21/tetraphase-said-to-explore-sale-after-takeover-interest.html

Tetraphase Pharmaceuticals Inc. , a maker of antibiotics to treat serious infections, is exploring a sale after attracting interest from potential buyers, people familiar with the matter said.

The biotechnology company is working with advisers to explore its options, the people said, asking not to be identified because the deliberations are private. Tetraphase may attract interest from bidders including Actelion Ltd. and Roche Holding AG, the people said.

As its lead product, a urinary tract infection treatment called eravacycline, has shown promise, shares of the Watertown, Massachusetts-based company have risen over 63 percent this year. Tetraphase ended regular trading this week with a market capitalization of $677 million.

Separately, a 13G was filed today by Presidio Partners showing a 5.3% stake in TTPH as of 11/10/14 (http://www.sec.gov/Archives/edgar/data/1373707/000119312514420189/d825267dsc13g.htm ).